January 4, 2024 10:47 AM ESTUpdated January 5, 07:43 AM

Rhythm licenses obesity drug for $100M; Galapagos teams up with BridGene; Insilico’s new deal

ENDPOINTS

Plus, news about Boehringer Ingelheim, Merck KGaA, Atai Life Sciences, Resalis Therapeutics, Portage Biotech, Sensei Biotherapeutics and ADC Therapeutics:

Rhythm licenses obesity drug for …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rhythm licenses obesity drug for $100M; Galapagos teams up with BridGene; Insilico’s new deal

ENDPOINTS

Sign up to read this article for free.

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

CBER's deputy director departs as staff shakeup continues

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

Will CRISPR matter?

FDA approves first drug to treat ultra-rare lipid storage disease

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

Rhythm licenses obesity drug for $100M; Galapagos teams up with BridGene; Insilico’s new deal